33 results about "Lanosterol" patented technology

The present invention relates to the electrochemical oxidation of allylic C- H bonds in specific compounds to obtain specific α,β unsaturated ketones in the presence of t-butyl hydroperoxide. This process is particularly suitable for the electrochemical oxidation of cholesterol, stigmasterol, campesterol, β-sitosterol, brassicasterol, 25-hydroxycholesterol, 24-hydroxycholesterol, lanosterol, pregnenolone, and the esters thereof.

The invention relates to the technical field of medicines, and provides a lanosterol derivative as well as a preparation method and application thereof. The lanosterol derivative provided by the invention has a structural formula as shown in a formula I or a formula II. The lanosterol derivative provided by the invention has both fat solubility and water solubility, and can effectively permeate into a diseased region in a body, so that the medicinal availability is improved; results of the embodiment show that the solubility of the lanosterol derivative provided by the invention in water is obviously higher than that of lanosterol or 25-hydroxylanosterol, and the lanosterol derivative shows an obvious cataract treatment effect in animal in-vivo experiments and has a wide prospect in preparation of drugs for treating eye diseases or symptoms. # imgabs0 #

An ophthalmic formulation for preventing and treating cataracts contains an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient. The active substance is oxidized cholesterol, including lanosterol or 25-hydroxycholesterol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent, and a solvent; the content of the oxidized cholesterol in the formulation is 0.01-5 mg / mL; and the mass ratio of the surfactant, the tackifier, the cosolvent, and the oxidized cholesterol is (1-300):(1-100):(100-3000):1, with the balance being the solvent. Upon eye drop administration, the formulation can cause the active substance to be selectively enriched in the lens of a laboratory animal to accurately exert the effect of treating cataracts. The active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding toxic and side effects on other eye tissue and the whole body.

The application discloses a kit for diagnosing systemic lupus erythematosus, which is lanosterol lipid metabolite key enzyme CYP51A1, the expression amount of the transcription level of the lanosterol lipid metabolite key enzyme CYP51A1, and the cDNA sequence of the lanosterol lipid metabolite key enzyme CYP51A1 is shown as SEQ ID No. 1. The kit for diagnosing SLE provided by the application comprises CYP51A1 gene primers and primers of a housekeeping gene GAPDH, a standard product and amplification reagents. The application overcomes the defect that SLE gene diagnosis cannot be diagnosed. The application adopts a real-time fluorescent quantitative PCR method, has the characteristics of rapidness, sensitivity, accuracy and the like, the expression of CYP51A1 is detected through real-time fluorescent quantitative PCR, important basis and reference value can be provided for clinical diagnosis of diseases, thus being beneficial to the formulation of a treatment scheme of the disease, and having popularization and application value.

The present invention relates to a pharmaceutical dosage form comprising lanosterol and a derivative thereof, and cyclodextrin, the pharmaceutical dosage form according to one embodiment having an effect of improving water solubility and in vivo absorbability, thereby increasing bioavailability.

The application discloses application of lanosterol derivatives with the following structure in preparation of drugs for treating retinal degenerative diseases. A novel compound, lanosterol derivative L7, is synthesized by reasonably modifying a lanosterol mother nucleus structure, and the bioavailability and retinal targeting property of the lanosterol derivative L7 are significantly improved, and the lanosterol derivative L7 can significantly improve retinal degeneration and shows better safety and effectiveness.

A composition includes a compound as shown in formula (I). The compound and composition can be used in the preparation of a drug for treating ophthalmic diseases.

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The invention relates to a preparation method and application of ganoderma lucidum spore fermentation oil, and the preparation method comprises the following steps: fermenting lactobacillus, recombinant saccharomycetes and ganoderma lucidum spore oil together, and separating an oil phase to obtain the ganoderma lucidum spore fermentation oil, wherein squalene epoxidase, lanosterol synthetase and cytochrome P450 enzyme are expressed in the recombinant saccharomycetes. The ganoderma lucidum spore fermentation oil prepared by the preparation method can improve the skin feeling of ganoderma lucidum spore oil, increases the content of ganoderma lucidum triterpenes in the ganoderma lucidum spore oil, and can be better applied to cosmetics.

The present application relates to the technical field of medicine, and provides a lanosterol derivative, a preparation method and application thereof.The structural formula of the lanosterol derivative provided by the present application is shown as formula I or formula II.The lanosterol derivative provided by the present application has both fat solubility and water solubility, can effectively penetrate into the pathological site in the body, and improves the drug utilization degree;the results of examples show that the solubility of the lanosterol derivative provided by the present application in water is obviously higher than that of lanosterol or 25-hydroxy lanosterol, and the lanosterol derivative shows obvious cataract treatment effect in animal body experiments, and has a broad prospect in the preparation of drugs for treating eye diseases or conditions.

The invention belongs to the technical field of medicines, and discloses a preparation method of a series of compounds which have the effect of increasing the content of lanosterol in the brain and have general formulas (I) and (II) as well as a pharmaceutical composition and application of the compounds.

The invention discloses an application of a lanosterol derivative with a structure shown in the specification in preparation of a medicine for treating retinal degenerative diseases: a novel compound lanosterol derivative L7 is synthesized by reasonably modifying a lanosterol mother nucleus structure, so that the bioavailability and the retina targeting property of the lanosterol derivative L7 are remarkably improved; retinal degeneration can be remarkably improved, and better safety and effectiveness are shown.

The invention relates to a gynostemma pentaphylla oxidized squalene cyclase gene GpOSC2 and application thereof, and belongs to the technical field of genes. The amino acid sequence of the gynostemma pentaphylla oxidized squalene cyclase GpOSC2 is as shown in SEQ ID NO. 1. A coding sequence for coding the gynostemma pentaphylla oxidized squalene cyclase GpOSC2 gene is a nucleotide sequence as shown in SEQ ID NO. 2. According to the present invention, the gene is adopted to carry out fermentation so as to obtain Dammarenediol-II, lupeol, lanosterol, cycloartenol and alpha-amyrin alcohol, such that the application prospect is good, and the promotion and the application are easy.

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The invention relates to the technical field of biology, in particular to construction and application of a recombinant strain for synthesizing veratrazine and steroid precursors of the veratrazine, and the steroid precursors comprise squalene, ergosterol, lanosterol, 22R-hydroxy cholesterol, 22R, 26-dihydroxy cholesterol and 22-hydroxy-26-amino-cholesterol. The recombinant strain provided by the invention can efficiently express steroid precursors, for example, the content of lanosterol reaches 172mg / L and is increased by about 170 times compared with that of an original strain, the yield of 22R-hydroxycholesterol reaches 3482.83 mu g / L, the yield of 22R, 26-dihydroxycholesterol reaches 1003.05 mu g / L, veratrazine can be efficiently synthesized, and the yield of veratrazine reaches 265.38 mu g / L.

The application provides an eye preparation for preventing and treating cataract by eye drop, which is composed of an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient; the active substance for treating eye diseases is oxidized cholestanol, including lanosterol or 25-hydroxycholestanol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent and a solvent; the content of the oxidized cholestanol in the preparation is 0.01-5 mg / mL; the mass ratio of the surfactant, the tackifier, the cosolvent and the oxidized cholestanol is (1-300):(1-100):(100-3000):1, and the rest is the solvent. After the eye drop of the preparation, the active substance can be selectively enriched in the lens of experimental animals, so that the effect of treating cataract can be accurately exerted, and the active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding the toxic and side effects on other eye tissues and the whole body. The application solves the technical problem which people in the field of ophthalmic drug delivery have been eager to solve but have failed to obtain success, and has a very high clinical application value and social value.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant escherichia coli for efficiently biosynthesizing lanosterol as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: introducing exogenous squalene synthase (SQS), squalene epoxidase (SE) and oxidized squalene cyclase (OSC) genes into escherichia coli to construct a complete lanosterol synthesis route; the method comprises the following steps of: enhancing MEP pathway rate-limiting enzymes, namely 1-deoxy-D-xylulose-5-phosphate synthase (DXS), isopentenyl pyrophosphate isomerase (IDI) and farnesyl pyrophosphate synthase (FPS), so as to increase precursor supply, and further regulating and controlling the expression of key enzyme genes by adopting an arabinose promoter (PBAD). The lanosterol yield of the constructed engineering bacterium BW-2 reaches 8.02 mg / L and is increased by 40 times compared with that of an initial strain, and a brand new technical scheme is provided for green and efficient industrial production of lanosterol.

The invention provides a natural anti-aging composition, a color-changing lipstick containing the natural anti-aging composition and a preparation method of the color-changing lipstick. The natural anti-aging composition is prepared from 25 to 40 parts of meadowfoam seed oil, 1 to 10 parts of argania spinosa kernel oil, 15 to 25 parts of macadamia nut seed oil, 1 to 7 parts of sesame seed oil, 12 to 25 parts of C10-30 acid cholesteryl / lanosterol mixed ester, 15 to 30 parts of beewax and 0.01 to 2 parts of vitamin E. Test results show that the composition obtained through scientific and reasonable design has the effects of moisturizing, nourishing, resisting wrinkles, brightening color and the like, so that a good anti-aging effect is achieved. The color-changing lipstick developed by adopting the composition can bring good sensory experience, multi-dimensional anti-aging of lips can be realized after the lipstick is used, meanwhile, the appearance color of the lipstick body is mild, and the lipstick body presents different colors when being smeared by different people and is free of layering, breakage, silica gel marks, mimeograph and other undesirable phenomena. All the components in the composition are natural sources, so that the composition is mild, non-irritant, green and environment-friendly, and good guarantee is provided for the health of consumers and the environment.

The invention discloses a method for extracting a lanosterol crude product from wool fat. The method comprises the following steps: (1) mixing a first organic solvent with alkali and wool fat, and carrying out saponification reaction to obtain a saponified product; wherein the first organic solvent comprises an aromatic hydrocarbon organic solvent and an alcohol solvent; and (2) carrying out complexation reaction and crystallization on the saponified product obtained in the step (1) to obtain a lanosterol crude product. The extraction method disclosed by the invention is simple in process and low in cost, the obtained lanosterol is high in yield and purity, and the extraction method disclosed by the invention is large in sample separation amount, stable in process and suitable for industrial production.

This invention provides the application of lanosterols in the preparation of feed additives for bony fish and the feed itself, including lanosterols or their feed-acceptable esters, in the preparation of feed additives for bony fish to improve the growth performance, muscle quality, and physiological health of bony fish, including enhancing their antioxidant capacity and / or immunity. This invention provides a novel, efficient, and cost-optimized functional additive for bony fish feed, offering an effective cholesterol alternative or supplement to reduce feed costs; simultaneously, it significantly improves the growth performance and muscle quality of bony fish, enhances immune function and stress resistance, thereby improving aquaculture efficiency and feed utilization.

This invention provides the application of lanosterols in the preparation of crustacean feed additives and related feeds, including lanosterols or their feed-acceptable esters, in the preparation of crustacean feed additives to improve the growth performance and maintain the physiological health of crustaceans, including regulating lipid metabolism, enhancing antioxidant capacity, and / or improving digestive enzyme activity. This invention provides a novel, efficient, and cost-optimized functional additive for crustacean feed, offering an effective cholesterol alternative or supplement to reduce feed costs; and significantly improving the growth performance of crustaceans under low-fishmeal feed conditions while systematically regulating and maintaining their physiological health.

The invention discloses a purification method of lanosterol, which comprises the following steps: (a) acylating a lanosterol crude product to obtain an acylated crude product, (b) oxidizing the acylated crude product to obtain an oxidized crude product containing a compound shown as a formula III and a compound shown as a formula II, (c) carrying out separation treatment on the oxidized crude product containing the compound shown in the formula III and the compound shown in the formula II to respectively obtain the compound shown in the formula III and the compound shown in the formula II; and (d) converting the separated compound as shown in the formula III into lanosterol. The method is simple in process, convenient to operate, high in yield, high in purity, cheap and easily available in raw materials and suitable for industrialization; and the whole process is more economical and environment-friendly.

The invention discloses a process for affinity separation of active components in inonotus obliquus by using a VEGFR2 extracellular domain and application, and relates to the technical field of active component extraction.The process comprises the steps that eight active components including echinacoside, trilliin, typhaenoside, hederagenin, asiaticoside, lanosterol, betulin and aster ketone are selected; the inhibition effect of the compound on cervical cancer cells is studied. The method comprises the following steps: taking a sample to be detected, taking a detection solution, carrying out lauryl sodium sulfate-polyacrylamide gel electrophoresis and Western blot analysis, determining the protein expression quantity of VEGFR-2 related pathways, and researching the regulating effects of trillioside, betulin, hederagenin and lanosterol on a PI3K / AKT signal pathway, a PLC gamma / ERK signal pathway, Bad protein, Caspase-9 protein and Cleaved Caspase-9 protein of SiHa cells.

The invention discloses a separation and purification method of a lanosterol crude product. The method comprises the following steps: separating and purifying a lanosterol crude product solution by using preparative liquid chromatography to obtain a lanosterol pure product; wherein a mobile phase used for preparing the liquid chromatogram comprises a solvent 1 and acetonitrile; the solvent 1 is selected from one or more of methanol, ethanol, normal propyl alcohol, isopropanol and dichloromethane. The method disclosed by the invention has relatively good selectivity on separation and purification of lanosterol, the process is simple, the implementation is easy, the separation period is short, the separated lanosterol is high in purity and high in yield, efficient separation of lanosterol and dihydrolanosterol is realized, and the method has important significance on preparation of lanosterol monomers.

The present disclosure relates to a pharmaceutical formulation including lanosterol, a derivative thereof, and cyclodextrin. The pharmaceutical formulation, according to an aspect, exhibits enhanced water solubility and absorption in the body, and thus has the effect of increasing bioavailability.

The invention belongs to the technical field of cosmetics, and particularly relates to a non-whitening eyebrow pencil refill, a preparation method and an eyebrow pencil. The colorant powder in the raw materials of the non-whitening eyebrow pencil refill provided by the invention is coated with C10-30 acid cholesteryl / lanosterol mixed ester and sucrose tetrastearate triacetate in advance, so that the formation of critical crystal nucleuses and the growth of the crystal nucleuses of vegetable wax are promoted, more complete crystals are favorably formed, and the whitening effect of the eyebrow pencil refill is improved. According to the present invention, the vegetable wax is added, such that the crystallization process of the vegetable wax is improved, the compatibility of the coloring agent and the grease component is improved, the migration of the vegetable wax crystal and the precipitation of the grease are delayed, such that the eyebrow pencil refill does not easily produce white frost during the storage process, and the technical problem that the existing eyebrow pencil refill easily produces the whitening phenomenon during the storage process is solved.

The invention discloses a nitric oxide donor type lanosterol derivative as shown in a formula I and a preparation method and application thereof, and the nitric oxide donor type lanosterol derivative has dual functions of reducing intraocular pressure and protecting optic nerves and can be used for preparing a medicine for treating glaucoma diseases. Wherein R is selected from one of C2-C5 straight chain alkylene groups.

The invention discloses preparation and application of a Saccharomyces cerevisiae lanosterol 14 alpha-demethylase mutant, and belongs to the technical field of gene engineering and enzyme engineering. Starting from the Saccharomyces cerevisiae WQ6, the lanosterol 14 alpha-demethylase of the Saccharomyces cerevisiae is mutated by means of genetic engineering and enzyme engineering, the yield of ergosterol of the Saccharomyces cerevisiae can be increased by the obtained single mutation and double mutants, and conditions are created for expanding industrial application of the lanosterol 14 alpha-demethylase of the Saccharomyces cerevisiae.

The application discloses a process for affinity separation of active ingredients in Inonotus obliquus by using an extramembrane region of VEGFR2 and application thereof, and relates to the technical field of active ingredient extraction. Eight active ingredients, namely echinacoside, strophanthin, typhonioside, hederagenin, asiaticoside, lanosterol, betulinol and shionin, are selected to study the inhibiting effect of the active ingredients on cervical cancer cells. The detection liquid is taken to perform sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis, the expression amount of VEGFR-2 related pathway proteins is determined, and the regulation effects of strophanthin, betulinol, hederagenin and lanosterol on the PI3K / AKT signal pathway, the PLC gamma / ERK signal pathway, Bad protein, Caspase-9 protein and Cleaved Caspase-9 protein of SiHa cells are studied.

The invention discloses a recombinant Yarrowia lipolytica engineering strain for producing ergosterol and application of the recombinant Yarrowia lipolytica engineering strain, and belongs to the technical field of genetic engineering and bioengineering. According to the method, sterol synthesis route genes are screened, the speed limiting step is determined, high-yield ergosterol is preliminarily achieved through combined expression, the flow direction of carbon metabolic flow is further pulled through lipid droplet engineering and cell area chamber engineering, and the yield of ergosterol is increased. On the basis of enzyme modification engineering, the catalytic efficiency of the ERG11 on the lanosterol is improved through substrate channel engineering and proton-dependent catalytic path construction. Through multi-copy integration of the genes in the speed limiting step, the yield of ergosterol in a shake flask of the constructed engineering strain reaches 433.1 mg / L, and the yield of ergosterol in a 5L fermentation tank system reaches 4.58 g / L.